학술논문
Impact of Chronic Obstructive Pulmonary Disease in Patients With Heart Failure With Preserved Ejection Fraction: Insights From PARAGON‐HF
Document Type
article
Author
Leanne Mooney; Nathaniel M. Hawkins; Pardeep S. Jhund; Margaret M. Redfield; Muthiah Vaduganathan; Akshay S. Desai; Jean L. Rouleau; Masatoshi Minamisawa; Amil M. Shah; Martin P. Lefkowitz; Michael R. Zile; Dirk J. Van Veldhuisen; Marc A. Pfeffer; Inder S. Anand; Aldo P. Maggioni; Michele Senni; Brian L. Claggett; Scott D. Solomon; John J. V. McMurray
Source
Journal of the American Heart Association: Cardiovascular and Cerebrovascular Disease, Vol 10, Iss 23 (2021)
Subject
Language
English
ISSN
2047-9980
Abstract
Background Little is known about the impact of chronic obstructive pulmonary disease (COPD) in patients with heart failure with preserved ejection fraction (HFpEF). Methods and Results We examined outcomes in patients with heart failure with preserved ejection fraction, according to COPD status, in the PARAGON‐HF (Prospective Comparison of Angiotensin Receptor Neprilysin Inhibitor With Angiotensin Receptor Blocker Global Outcomes in Heart Failure With Preserved Ejection Fraction) trial. The primary outcome was a composite of first and recurrent hospitalizations for heart failure and cardiovascular death. Of 4791 patients, 670 (14%) had COPD. Patients with COPD were more likely to be men (58% versus 47%; P